Skip to main content

NeuroAiD is safe and well tolerated.

The safety profile of NeuroAiD is now well established. All clinical studies have reported NeuroAiD as a safe product, without severe adverse events and with only rare and transitory gastro-intestinal discomfort (e.g., nausea, vomiting) in subjects with sensitive digestive transit.

NeuroAiD has no impact on hepatic and renal functions, cardiovascular parameters, and other biological parameters1,2

NeuroAiD is not competing nor interacting with other medications. It can be safely combined with standard medications used in stroke, traumatic brain injury and spinal cord injury patients 1,3,6. It is also a safe add-on treatment to standard Alzheimer’s Disease medications 7.

No increase in the rates of delayed adverse events has been reported in several long-term studies for stroke, spinal cord injury and Alzheimer’s Disease 8-11.

Always seek advice from your physician.


1. . Young S, et al. Safety profile of MLC601 (NeuroAiD) in acute ischemic stroke patients: A Singaporean substudy of the Chinese medicine NeuroAiD efficacy on stroke recovery study. Cerebrovascular Diseases. 2010;30:1-6.

2. Gan R, et al. Danqi Piantan Jiaonang does not modify haemostasis, haematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases. 2008;25:450-456.

3. Chen C, et al. Chinese medicine NeuroAiD efficacy on stroke recovery: A double-blind, placebo-controlled, randomized study. Stroke. 2013a;44:2093-2100

4. Theadom A, et al. MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial. Eur J Neurol. 2018 Aug;25(8):1055-e82.

5. Fauzi AA, et al. Clinical Outcomes of MLC601 (NeuroAiDTM) in Traumatic Brain Injury: A Pilot Study. Brain Sci. 2020 Jan 21;10(2):60.

6. Kumar R, et al. Spinal cord injury – assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study – primary results of an exploratory study. J Spinal Cord Med. 2022 May 23:1-5.

7. Chen CLH, et al. Alzheimer’s Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial. J Am Med Dir Assoc. 2022 Mar;23(3):379-386.e3.

8. Venketasubramanian N, et al. CHInese medicine NeuroAiD efficacy on stroke recovery – Extension study (CHIMES-E): A multicenter study of long-term efficacy. Cerebrovascular Diseases. 2015;39:309-318.

9. Shahripour RB, et al. A Randomized Trial to Assess the Long-Term Safety of NeuroAiD among Caucasian Patients with Acute Ischemic Stroke. Chin J Integr Med. 2014;20(11): 812-817.

10. Kumar R et al. Long-Term Outcomes of the Spinal Cord Injury Assessing Tolerability and Use of Combine Rehabilitation and NeuroAID (SATURN STUDY). J Spine Research and Surgery. 2023;5(2).

11. Pakdaman H, et al. A long-term study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer’s disease; An Extension 8-year Follow-up Study. Curr Aging Sci. 2023 Feb 24.


Disclaimers:  NeuroAiD™ II is a trademark of Moleac. MLC601 and MLC901 are 2 different proprietary formulations which have been shown to be equivalent in pharmacology and are referred as NeuroAiD on this webpage.

Find-out if NeuroAiD is right for you.

Leave your questions to our Customer Care team by clicking on the box below. Always seek advice from your physician.

NAII 3 e1613530758649